The importance of meropenem resistance, rather than imipenem resistance, in defining carbapenem-resistant Enterobacterales for public health surveillance: an analysis of national population-based surveillance.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Imipenem*/pharmacology ; Anti-Infective Agents*; Humans ; Meropenem/pharmacology ; Public Health Surveillance ; Bacterial Proteins/genetics ; beta-Lactamases/genetics ; Cefmetazole ; Escherichia coli ; Microbial Sensitivity Tests ; Anti-Bacterial Agents/pharmacology

Background: In Japan, carbapenem-resistant Enterobacterales (CRE) infections were incorporated into the National Epidemiological Surveillance of Infectious Diseases (NESID) in 2014, necessitating mandatory reporting of all CRE infections cases. Subsequently, pathogen surveillance was initiated in 2017, which involved the collection and analysis of CRE isolates from reported cases to assess carbapenemase gene possession. In this surveillance, CRE is defined as (i) minimum inhibitory concentration (MIC) of meropenem ≥2 mg/L (MEPM criteria) or (ii) MIC of imipenem ≥2 mg/L and MIC of cefmetazole ≥64 mg/L (IPM criteria). This study examined whether the current definition of CRE surveillance captures cases with a clinical and public health burden.
Methods: CRE isolates from reported cases were collected from the public health laboratories of local governments, which are responsible for pathogen surveillance. Antimicrobial susceptibility tests were conducted on these isolates to assess compliance with the NESID CRE definition. The NESID data between April 2017 and March 2018 were obtained and analyzed using antimicrobial susceptibility test results.
Results: In total, 1681 CRE cases were identified during the study period, and pathogen surveillance data were available for 740 (44.0%) cases. Klebsiella aerogenes and Enterobacter cloacae complex were the dominant species, followed by Klebsiella pneumoniae and Escherichia coli. The rate of carbapenemase gene positivity was 26.5% (196/740), and 93.4% (183/196) of these isolates were of the IMP type. Meanwhile, 315 isolates were subjected to antimicrobial susceptibility testing. Among them, 169 (53.7%) fulfilled only the IPM criteria (IPM criteria-only group) which were susceptible to meropenem, while 146 (46.3%) fulfilled the MEPM criteria (MEPM criteria group). The IPM criteria-only group and MEPM criteria group significantly differed in terms of carbapenemase gene positivity (0% vs. 67.8%), multidrug resistance rates (1.2% vs. 65.8%), and mortality rates (1.8% vs 6.9%).
Conclusion: The identification of CRE cases based solely on imipenem resistance has had a limited impact on clinical management. Emphasizing resistance to meropenem is crucial in defining CRE, which pose both clinical and public health burden. This emphasis will enable the efficient allocation of limited health and public health resources and preservation of newly developed antimicrobials.
(© 2024. The Author(s).)

J Infect Dis. 2017 Feb 15;215(suppl_1):S28-S36. (PMID: 28375512)
Int J Antimicrob Agents. 2020 Oct;56(4):106126. (PMID: 32755654)
Euro Surveill. 2017 Nov;22(46):. (PMID: 29162208)
PLoS One. 2016 Apr 22;11(4):e0154092. (PMID: 27104910)
Int J Appl Basic Med Res. 2017 Jan-Mar;7(1):32-39. (PMID: 28251105)
Infection. 2019 Jun;47(3):363-375. (PMID: 30840201)
Sci Rep. 2020 Mar 5;10(1):4139. (PMID: 32139745)
J Antimicrob Chemother. 2020 Aug 1;75(8):2334-2343. (PMID: 32417924)
J Glob Antimicrob Resist. 2022 Jun;29:247-252. (PMID: 35429667)
Microb Drug Resist. 2018 Nov;24(9):1277-1283. (PMID: 29653477)
Antimicrob Agents Chemother. 2018 Jan 25;62(2):. (PMID: 29203488)
Appl Environ Microbiol. 2016 Jan 08;82(6):1818-1827. (PMID: 26746714)
Lancet Infect Dis. 2020 Jun;20(6):731-741. (PMID: 32151332)
J Antimicrob Chemother. 2020 Mar 1;75(3):697-708. (PMID: 31789374)
Antibiotics (Basel). 2021 Sep 30;10(10):. (PMID: 34680770)
Clin Infect Dis. 2017 Feb 1;64(3):257-264. (PMID: 28013264)
J Infect Chemother. 2018 Jun;24(6):414-421. (PMID: 29428566)
Clin Infect Dis. 2019 Sep 27;69(8):1446-1455. (PMID: 30838380)
Lancet Infect Dis. 2018 Mar;18(3):e99-e106. (PMID: 29102325)
Lancet Infect Dis. 2019 Jun;19(6):601-610. (PMID: 31047852)
Infect Drug Resist. 2019 Jul 16;12:2113-2123. (PMID: 31406467)

Investigator: M Matsui; S Suzuki; Y Takahashi; N Kamitaka; S Takahashi; N Kanno; T Ishi; R Shimada; H Takahashi; M Ogawa; K Kikuchi; H Ueno; K Tomari; J Yoshihara; N Ando; T Katakura; Y Matsumoto; Y Anzawa; S Haruna; M Hosoya; M Watahiki; M Shiroza; K Yokoyama; M Noda; A Furuta; R Kawahara; K Umeda; T Yamaguchi; N Nakanishi; K Kuroda; E Saito; Y Inoue; Y Kawakami; T Aota; K Masuda; H Ohtsuka; C Fukuda; K Seki; Y Iwashita; Y Asano; Y Fukuguchi; E Arikawa; R Maeda; T Kudeken
Keywords: Carbapenem-resistant Enterobacterales; Carbapenemase-producing Enterobacterales; IMP-type metallo-β-lactamase; Imipenem; Meropenem; Multidrug resistance; Surveillance definition

FV9J3JU8B1 (Meropenem)
71OTZ9ZE0A (Imipenem)
0 (Bacterial Proteins)
EC 3.5.2.6 (beta-Lactamases)
3J962UJT8H (Cefmetazole)
0 (Anti-Infective Agents)
0 (Anti-Bacterial Agents)

Date Created: 20240215 Date Completed: 20240219 Latest Revision: 20240219

20240219

PMC10870673

10.1186/s12879-024-09107-4

38360618